Acadian Asset Management’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-25,390
Closed -$2M 2129
2025
Q4
$2M Sell
25,390
-3,055
-11% -$208K ﹤0.01% 912
2025
Q3
$957K Sell
28,445
-91,679
-76% -$2.26M ﹤0.01% 1066
2025
Q2
$1.71M Sell
120,124
-72,374
-38% -$936K ﹤0.01% 870
2025
Q1
$2.69M Buy
192,498
+49,023
+34% +$666K 0.01% 685
2024
Q4
$2.21M Buy
143,475
+89,383
+165% +$1.36M 0.01% 741
2024
Q3
$846K Buy
+54,092
New +$760K ﹤0.01% 959

Other funds holding INBX

Acadian Asset Management's INBX Position: Q1 2026 in Review

Acadian Asset Management sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 25,390 shares — an estimated $2M sold.

Acadian Asset Management first reported a position in INBX in Q3 2024 and held it in 6 quarters. The position peaked at $2.69M in Q1 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Acadian Asset Management reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 25,390 Inhibrx shares in Q1 2026, an estimated $2M.
  • Acadian Asset Management first reported a position in Inhibrx in Q3 2024 and held it in 6 quarters.
  • Acadian Asset Management's Inhibrx position peaked at $2.69M in Q1 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.